References
- Home Office. Updated Drug Strategy. Home Office, London, UK (2002).
- ONDCP. The Economic Cost of Drug Abuse in the United States, 1992–2002. Office of National Drug Control Policy, DC, USA (2004).
- Gordon L, Tinsley L, Godfrey C, Parrott S. The economic and social costs of Class A drug use in England and Wales, 2003/4. In: Measuring Different Aspects of Problem Drug Use: Methodological developments. Singleton N, Murray R, Tinsley L (Eds). Home Office, London, UK (2006).
- Harrison PA. Predisposing factors. In: Manual of Substance Abuse Treatment. Estroff TW (Ed.). American Psychiatric Publishing, DC, USA (2001).
- Sullivan TN, Farrell AD. Risk factors. In: Substance Abuse and Dependence in Adolescence. Essau CA(Ed.). Taylor & Francis, Inc., NY, USA (2002).
- Toumbourou JW, Catalano RF. Predicting developmentally harmful substance use. In: Preventing Harmful Substance Use: The Evidence Base for Policy and Practice. Stockwell T, Gruenewald P, Toumbourou JW, Loxley W (Eds). Wiley, London, UK (2005).
- Chivite-Matthews N, Richardson A, O’Shea J et al.Drug Misuse Declared: Findings from the British Crime Survey 2003/04, England and Wales. Home Office, London, UK (2005).
- Ramsay M, Partridge S, Byron C. Drug Misuse Declared in 1998: Results from the British Crime Survey, Home Office Research Study No. 197. Home Office, London, UK (1999).
- Department of Health. Out of Sight? Not Out of Mind: Children, Young People and Volatile Substance Abuse (VSA). Department of Health, London, UK (2005).
- Godfrey C, Eaton C, McDougall C et al.The Economic and Social Costs of Class A Drug Use in England and Wales, 2000. Home Office, London, UK (2002).
- Belfield CR, Mores M, Barnett S, Schweinhart L. The high/scope perry preschool program: cost–benefit analysis using data from the age-40 follow-up. J. Hum. Resour.41(1), 162–190 (2006).
- Matrix RCL. Modelling the Cost-Effectiveness of Community-Based Substance Misuse Interventions for Vulnerable Young People. NICE, London, UK (2006).
- Robertson AA, Grimes PW, Rogers KE. A short-run cost-benefit analysis of community-based interventions for juvenile offenders. Crime Delinq.47(2), 265–284 (2001).
- Dennis M, Godley SH, Diamond G et al. The Cannabis Youth Treatment (CYT) study: main findings from two randomised trials. J. Subst. Abuse Treat.27(3), 197–213 (2004).
- Swisher JD. A cost–effectiveness comparison of two approaches to life skills training. J. Alcohol Drug Educ.48(1), 71–80 (2004).
- Cohen MA. The monetary value of saving a high risk youth. J. Quantitative Criminol.14(1), 5–33 (1998).
- Schildhaus S, Shaw-Taylor Y, Pedlow S, Pergamit MR. Predicting Heavy Drug Use: Results of a Longitudinal Study, Youth Characteristics Describing and Predicting Heavy Drug Use by Adults. Office of National Drug Control Policy, DC, USA (2004).
- Brook J. Risk factors for adolescent Marijuana use across cultures and across time. J. Genet. Psychol.162(3), 357–374 (2001).
- Culyer A, Eaton G, Godfrey C, Koutsolioutsos H, McDougall C. Economic and social cost of substance misuse in the United Kingdom: review of the methodological and empirical studies of the economic and social costs of illicit drugs. In: University of York, Report to the Home Office. York, UK (2002).
- Dubourg R, Hamed J, Thorns J. The Economic and Social Costs of Crime Against Individuals and Households 2003/04. Home Office, London, UK (2005).
- Mandilia S, Brettle R, Fisher M et al. Cause and time to treatment failure of HAART and cost of care in UK NPMS-HHC clinics, 1996–2002. HIV Med.7(Suppl. 1), (2006) (Abstract 033).
- Steinke DT, Weston TL, Morris AD, MacDonald TM, Dillon JF. Epidemiology and economic burden of viral hepatitis: an observational population based study. Gut50(1), 100–105 (2002).
- Shepherd J, Brodin HFT, Cave CB, Waugh NR, Price A, Gabbay J. Clinical- and cost–effectiveness of pegylated interferon-α in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int. J. Technol. Assess. Health Care21(1), 47–54 (2005).
- Gossop M, Marsden J, Stewart D. NTORS After Five Years. National Addiction Centre, London, UK (2001).
- Coid J, Carvell A, Kittler Z, Healey A, Henderson J. Opiates, Criminal Behaviour and Methadone Treatment. Research study, Home office, London, UK (2000).
- Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ329, 224–227 (2004).
- Dolan P, Loomes G, Peasgood T, Tsuchiya A. Estimating the intangible victim costs of violent crime. Br. J. Criminol.45, 958–976 (2005).
- HM Treasury. The Green Book. HM Treasury, London, UK (2003).
- NICE. Guide to the Methods of Technology Appraisal. NICE, London, UK (2004).
Websites
- Drugscope www.drugscope.org.uk
- Home Office www.homeoffice.gov.uk
- National Institute on Drug Abuse www.nida.nih.gov
- Health Economic Study Group www.hesg.org.uk/index.php
- Tufts-New England Medical Center, Catalogue of Preference Weights 1998–2000 www.tufts-nemc.org/cearegistry/links.html
- Centre for HIV information http://hivinsite.ucsf.edu/insite?page=ask-06–02–07
- Treatment and Care for Chronic Hepatitis B Virus (HBV) Infection www.hivandhepatitis.com/doctor/topics/hbv1.html
- UK Hep C Resource Centre www.hepccentre.org.uk/documents/uk%20hep%20c%20info%20pack%20sept%2004.pdf
- UK Statistics Authority www.statistics.gov.uk
- Carter M. HIV prevalence increases by 20% in UK in one year www.aidsmap.com/en/news/e9008eaf-591b-474c-9898–4de68c60396d.asp
- Willacy H. Hepatitis B vaccination and Hepatitis B prevention www.patient.co.uk/showdoc/40000893
- CEP The Depression Report: a New Deal for Depression and Anxiety Disorders http://cep.lse.ac.uk/textonly/research/mentalhealth/depression_report_layard.pdf
- ONS Unemployment statistics www.statistics.gov.uk/cci/nugget.asp?id=12
- Aidsmap: latest news www.aidsmap.com/en/news/e9008eaf-591b-474c-9898–4de68c60396d.asp
- Mid-2004 Population Estimates: United Kingdom; estimated resident population by single year of age and sex; revised due to Harrow correction – 20 December 2005 www.statistics.gov.uk/statbase/expodata/spreadsheets/d9081.xls
- Patient UK: Hepatitis B Vaccination and Hepatitis B Prevention www.patient.co.uk/showdoc/40000893
- Rumbelow H, Miles A. When caring clashes with costs – the nasty business of being NICE. The Times, 13 January (2007) www.timesonline.co.uk/to1/newspapers/sundaytimes/britain/article1292310.ece